Early-stage Life Science Investment by Domain Experts
Many investors and strategics have shifted downstream, creating a gap & opportunity for specialized investors who can engage & invest early. Our model is built on highly-specialized industry expertise, enabling us to identify and accelerate opportunities prior to key inflection points.
MedTech Investment Profile: We target solutions that unlock significant value for acquirers, and have the following characteristics:
Potential exit >$250M in companies with transformational solutions
Investing before human Proof-of-concept and <5Y to liquidity
Opportunistic in all Medtech segments, yet requiring transformational differentiation
Biopharma Investment Profile: We invest in disease areas that are related to our MedTech expertise, and where smaller FDA trials will provide early indications of efficacy.